Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers CertaraMarch 9, 2026
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…CertaraMarch 6, 2026
Understanding and Calculating Steady State Pharmacokinetics BlogKnowledge Base Understanding and Calculating Steady State Pharmacokinetics Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…CertaraMarch 5, 2026
Phoenix Roadshow 2026 – Raleigh/Durham Live Events Phoenix Roadshow 2026 – Raleigh/Durham CertaraMarch 2, 2026
Phoenix Roadshow 2026 – Philadelphia Live Events Phoenix Roadshow 2026 – Philadelphia CertaraFebruary 27, 2026
Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) On-Demand Webinar Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…CertaraFebruary 27, 2026
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle PillsburyFebruary 23, 2026
Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) Webinar Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) CertaraFebruary 23, 2026